# Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

> **NCT05931393** · PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 18 (estimated)

## Conditions studied

- RCC
- Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib 80 MG

## Key facts

- **NCT ID:** NCT05931393
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-09-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05931393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05931393, "Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05931393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*